97 POSTER A phase I dose-escalation study of the safety and pharmacokinetics of a novel spectrum selective kinase inhibitor, XL820, administered orally to patients with solid tumors

A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors

Investigational New Drugs ◽

10.1007/s10637-017-0467-7 ◽

2017 ◽

Vol 36 (1) ◽

pp. 36-44 ◽

Cited By ~ 2

Author(s):

Janice M. Mehnert ◽

Gerald Edelman ◽

Mark Stein ◽

Heather Camisa ◽

Joanne Lager ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Tablet Formulation ◽

Dose Escalation Study ◽

Phosphoinositide 3 Kinase

Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3034 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3034-3034 ◽

Cited By ~ 12

Author(s):

T. R. J. Evans ◽

J. A. Morgan ◽

A. D. van den Abbeele ◽

I. R. J. McPherson ◽

S. George ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Kinase Inhibitor ◽

27 ORAL Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 6-hour infusion on days 1, 8 and 15 every 4 weeks in patients with advanced/metastatic solid tumors

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(06)70032-5 ◽

2006 ◽

Vol 4 (12) ◽

pp. 12 ◽

Cited By ~ 4

Author(s):

M. De Jonge ◽

N. Steeghs ◽

J. Verweij ◽

J.W.R. Nortier ◽

F. Eskens ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Aurora Kinase ◽

Aurora Kinase Inhibitor ◽

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-014-2380-5 ◽

2014 ◽

Vol 73 (3) ◽

pp. 539-549 ◽

Cited By ~ 96

Author(s):

Edward Sausville ◽

Patricia LoRusso ◽

Michael Carducci ◽

Judith Carter ◽

Mary F. Quinn ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Dose Escalation Study ◽

Checkpoint Kinase ◽

Checkpoint Kinase Inhibitor

Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.2540 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 2540-2540 ◽

Cited By ~ 7

Author(s):

D. S. Hong ◽

B. S. Koetz ◽

R. Kurzrock ◽

N. N. Senzer ◽

W. Hanekom ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer

Oncotarget ◽

10.18632/oncotarget.18554 ◽

2017 ◽

Vol 8 (45) ◽

pp. 79546-79555 ◽

Cited By ~ 8

Author(s):

Kohei Shitara ◽

Tae Min Kim ◽

Tomoya Yokota ◽

Masahiro Goto ◽

Taroh Satoh ◽

...

Keyword(s):

Gastric Cancer ◽

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Dose Escalation Study ◽

Asian Patients

A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-14-0409 ◽

2014 ◽

Vol 20 (24) ◽

pp. 6284-6294 ◽

Cited By ~ 18

Author(s):

L. Rhoda Molife ◽

Emma Jane Dean ◽

Montserrat Blanco-Codesido ◽

Matthew G. Krebs ◽

Andre T. Brunetto ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Receptor Tyrosine Kinase Inhibitor

Solid Tumors ◽

Dose Escalation ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Dose Escalation Study ◽

Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-016-3056-0 ◽

2016 ◽

Vol 78 (1) ◽

pp. 83-90

Author(s):

Oliver E. Bechter ◽

Herlinde Dumez ◽

Jo Costermans ◽

Kevin Punie ◽

Karl Hsu ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Tablet Formulation ◽

Dose Escalation Study ◽

Phosphoinositide 3 Kinase

A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-012-2019-3 ◽

2012 ◽

Vol 71 (2) ◽

pp. 463-471 ◽

Cited By ~ 13

Author(s):

Raoul Tibes ◽

Gil Fine ◽

Gavin Choy ◽

Sanjeev Redkar ◽

Pietro Taverna ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Dose Escalation Study ◽

Human Dose

Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.2531 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 2531-2531 ◽

Cited By ~ 6

Author(s):

T. Evans ◽

C. R. Lindsay ◽

E. Chan ◽

B. Tait ◽

S. A. Michael ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Phase I ◽

Insulin Receptor ◽

Solid Tumors ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽